CA2263838A1 - Crystal structures of a protein tyrosine kinase - Google Patents

Crystal structures of a protein tyrosine kinase Download PDF

Info

Publication number
CA2263838A1
CA2263838A1 CA002263838A CA2263838A CA2263838A1 CA 2263838 A1 CA2263838 A1 CA 2263838A1 CA 002263838 A CA002263838 A CA 002263838A CA 2263838 A CA2263838 A CA 2263838A CA 2263838 A1 CA2263838 A1 CA 2263838A1
Authority
CA
Canada
Prior art keywords
atom
tyrosine kinase
protein tyrosine
crystalline form
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002263838A
Other languages
English (en)
French (fr)
Inventor
Moosa Mohammadi
Li Sun
Congxin Liang
Joseph Schlessinger
Stevan R. Hubbard
Gerald Mcmahon
Peng C. Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
New York University NYU
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/701,191 external-priority patent/US5942428A/en
Application filed by Individual filed Critical Individual
Publication of CA2263838A1 publication Critical patent/CA2263838A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002263838A 1996-08-21 1997-08-21 Crystal structures of a protein tyrosine kinase Abandoned CA2263838A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/701,191 US5942428A (en) 1996-08-21 1996-08-21 Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
US08/701,191 1996-08-21
US3416896P 1996-12-19 1996-12-19
US60/034,168 1996-12-19
PCT/US1997/014885 WO1998007835A2 (en) 1996-08-21 1997-08-21 Crystal structures of a protein tyrosine kinase

Publications (1)

Publication Number Publication Date
CA2263838A1 true CA2263838A1 (en) 1998-02-26

Family

ID=26710643

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002263838A Abandoned CA2263838A1 (en) 1996-08-21 1997-08-21 Crystal structures of a protein tyrosine kinase

Country Status (5)

Country Link
EP (1) EP0931152A2 (ja)
JP (1) JP2001514484A (ja)
AU (1) AU733890B2 (ja)
CA (1) CA2263838A1 (ja)
WO (1) WO1998007835A2 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
SK287132B6 (sk) * 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6656696B2 (en) * 1999-02-26 2003-12-02 Cyclacel Compositions and methods for monitoring the phosphorylation of natural binding partners
US6972182B1 (en) * 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using coiled binding partners
US6670144B1 (en) * 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
US6828106B2 (en) * 1999-02-26 2004-12-07 Cyclacel Limited Methods and compositions using coiled binding partners
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
WO2000070030A1 (en) * 1999-05-19 2000-11-23 Amgen Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
WO2001016181A2 (en) * 1999-08-30 2001-03-08 New York University School Of Medicine Crystal structures of domains of receptor protein tyrosine kinases and their ligands
US7129072B1 (en) 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
US7369946B2 (en) 2000-03-29 2008-05-06 Abbott Gmbh & Co. Kg Method of identifying inhibitors of Tie-2
MXPA02009543A (es) * 2000-03-29 2005-08-26 Abbott Gmbh & Co Kg Metodo para identificar inhibidores de tie-2.
US6904369B1 (en) * 2000-06-29 2005-06-07 The Trustees Of Columbia University In The City Of New York Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor
US7736875B2 (en) 2000-09-08 2010-06-15 Prozymex A/S Dipeptidyl peptidase I crystal structure and its uses
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
BR0313078A (pt) 2002-08-06 2005-07-12 Astrazeneca Ab Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável
JP4915980B2 (ja) 2002-11-15 2012-04-11 エムユーエスシー ファウンデーション フォー リサーチ デベロップメント 補体レセプター２標的化補体調節因子
US20040253178A1 (en) * 2002-12-20 2004-12-16 Shane Atwell Crystals and structures of spleen tyrosine kinase SYKKD
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
WO2004078923A2 (en) * 2003-02-28 2004-09-16 Plexxikon, Inc. Pyk2 crystal structure and uses
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
EP1856252B1 (en) * 2005-03-08 2014-11-26 Boehringer Ingelheim International GmbH Crystallographic structure of mnk-1 and mnk-2 proteins
WO2006108270A1 (en) 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
KR20120130748A (ko) 2009-11-05 2012-12-03 알렉시온 캠브리지 코포레이션 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료
EP2569332B1 (en) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
JP6158092B2 (ja) 2010-12-16 2017-07-05 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ケモカイン受容体調節因子としての硫黄誘導体
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors

Also Published As

Publication number Publication date
EP0931152A2 (en) 1999-07-28
AU733890B2 (en) 2001-05-31
AU4160397A (en) 1998-03-06
JP2001514484A (ja) 2001-09-11
WO1998007835A3 (en) 1998-10-01
WO1998007835A2 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
CA2263838A1 (en) Crystal structures of a protein tyrosine kinase
WO1998007835A9 (en) Crystal structures of a protein tyrosine kinase
US5942428A (en) Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
JP7336178B2 (ja) 治療における使用のための新規のＴＮＦα構造
WO2003035846A2 (en) Structure of tall-1 and its cognate receptor
WO2004078923A2 (en) Pyk2 crystal structure and uses
WO2008068534A2 (en) Crystal structure of a betal -adremergi c receptor and uses thereof
CA2460151A1 (en) Cytokine receptor
CA2456236A1 (en) Methods of screening based on the egf receptor crystal structure
WO2017117118A1 (en) Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
WO2009055509A9 (en) Cholesterol consensus motif of membrane proteins
AU6960696A (en) Crystalline zap family proteins
WO2007010285A2 (en) Crystal structure of human soluble adenylate cyclase
WO2007075414A2 (en) Chemically derivatized cd4 and uses thereof
WO2007039761A2 (en) Crystal structure of cd44 and its use
KR101421089B1 (ko) 대장암에 특이적인 항암 활성을 갖는 신규 펩타이드, 이를 포함하는 ｎｄｒｇ２ 결정체 및 이의 용도
WO2016201566A1 (en) Systems and methods of selecting compounds with reduced risk of cardiotoxicity using herg models
WO2008037688A2 (en) Crystalline forms of pkc alpha kinase, methods of making such crystals, and uses thereof
WO2012097826A2 (en) Crystal structure of a type ib p-type atpase
JP2005137361A (ja) ペプチジルアルギニンデイミナーゼ４又はその変異体タンパク質の結晶、ペプチジルアルギニンデイミナーゼ４変異体タンパク質及びその複合体
WO2009076621A1 (en) High resolution structures of acidic mammalian chitinases and uses thereof
WO2012037150A1 (en) Crystal structures of o-glcnac transferase and uses thereof
WO2003006987A9 (en) Methods and compositions for determining enzymatic activity and specificity of methyltransferases
WO2006047505A2 (en) Crystal structure of the c-fms kinase domain
AU5660900A (en) Crystalline zap family proteins

Legal Events

Date Code Title Description
FZDE Discontinued